Covalent conjugation of the equine infectious anemia virus Gag with SUMO

Jinzhong Wang, Shuping Wen, Rui Zhao, Jing Qi, Zhao Liu, Weiwei Li, Jing An, Charles Wood, Ying Wang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The conjugation of small ubiquitin-like modifier (SUMO) to the target protein, namely, SUMOylation, is involved in the regulation of many important biological events including host-pathogen interaction. Some viruses have evolved to exploit the host SUMOylation machinery to modify their own protein. Retroviral Gag protein plays critical roles in the viral life cycle. The HIV-1 p6 and the Moloney murine leukemia virus CA have been reported to be conjugated with SUMO. In this study, we report for the first time, to our knowledge, the covalent conjugation of equine infectious anemia virus (EIAV) Gag with SUMO. The C-terminal p9 domain of Gag is a main target for SUMOylation and SUMO is attached to multiple sites of p9, including K30 whose mutation abolished p9 SUMOylation completely. The SUMOylation of p9, but not the p9-K30 mutant, was also detected in equine fibroblastic cells ATCC® CCL-57™. Ubc9 and its C93 residue are indispensable for the SUMOylation of p9. Using confocal microscopy, it is found that EIAV Gag localizes primarily, if not exclusively, in the cytoplasm of the cell and the co-localization of EIAV Gag with Ubc9 was observed. Our findings that EIAV Gag is SUMOylated at p9-K30, together with previous findings on the defects of p9-K30 mutant in viral DNA translocation from cytoplasm to the nucleus, suggests that SUMOylation of Gag may be involved in such functions.

Original languageEnglish (US)
Pages (from-to)712-719
Number of pages8
JournalBiochemical and Biophysical Research Communications
Volume486
Issue number3
DOIs
StatePublished - May 6 2017

Fingerprint

Equine infectious anemia virus
Sumoylation
Ubiquitin
Viruses
Cytoplasm
gag Gene Products
Moloney murine leukemia virus
Confocal microscopy
Host-Pathogen Interactions
Viral DNA
Pathogens
Machinery
Life Cycle Stages
Life cycle
Confocal Microscopy
Proteins
Horses
HIV-1
Defects
Mutation

Keywords

  • EIAV
  • Gag
  • K30
  • SUMO
  • Ubc9
  • p9

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Covalent conjugation of the equine infectious anemia virus Gag with SUMO. / Wang, Jinzhong; Wen, Shuping; Zhao, Rui; Qi, Jing; Liu, Zhao; Li, Weiwei; An, Jing; Wood, Charles; Wang, Ying.

In: Biochemical and Biophysical Research Communications, Vol. 486, No. 3, 06.05.2017, p. 712-719.

Research output: Contribution to journalArticle

Wang, Jinzhong ; Wen, Shuping ; Zhao, Rui ; Qi, Jing ; Liu, Zhao ; Li, Weiwei ; An, Jing ; Wood, Charles ; Wang, Ying. / Covalent conjugation of the equine infectious anemia virus Gag with SUMO. In: Biochemical and Biophysical Research Communications. 2017 ; Vol. 486, No. 3. pp. 712-719.
@article{713b02ee253942fcbd8151dcaa8662e8,
title = "Covalent conjugation of the equine infectious anemia virus Gag with SUMO",
abstract = "The conjugation of small ubiquitin-like modifier (SUMO) to the target protein, namely, SUMOylation, is involved in the regulation of many important biological events including host-pathogen interaction. Some viruses have evolved to exploit the host SUMOylation machinery to modify their own protein. Retroviral Gag protein plays critical roles in the viral life cycle. The HIV-1 p6 and the Moloney murine leukemia virus CA have been reported to be conjugated with SUMO. In this study, we report for the first time, to our knowledge, the covalent conjugation of equine infectious anemia virus (EIAV) Gag with SUMO. The C-terminal p9 domain of Gag is a main target for SUMOylation and SUMO is attached to multiple sites of p9, including K30 whose mutation abolished p9 SUMOylation completely. The SUMOylation of p9, but not the p9-K30 mutant, was also detected in equine fibroblastic cells ATCC{\circledR} CCL-57™. Ubc9 and its C93 residue are indispensable for the SUMOylation of p9. Using confocal microscopy, it is found that EIAV Gag localizes primarily, if not exclusively, in the cytoplasm of the cell and the co-localization of EIAV Gag with Ubc9 was observed. Our findings that EIAV Gag is SUMOylated at p9-K30, together with previous findings on the defects of p9-K30 mutant in viral DNA translocation from cytoplasm to the nucleus, suggests that SUMOylation of Gag may be involved in such functions.",
keywords = "EIAV, Gag, K30, SUMO, Ubc9, p9",
author = "Jinzhong Wang and Shuping Wen and Rui Zhao and Jing Qi and Zhao Liu and Weiwei Li and Jing An and Charles Wood and Ying Wang",
year = "2017",
month = "5",
day = "6",
doi = "10.1016/j.bbrc.2017.03.103",
language = "English (US)",
volume = "486",
pages = "712--719",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Covalent conjugation of the equine infectious anemia virus Gag with SUMO

AU - Wang, Jinzhong

AU - Wen, Shuping

AU - Zhao, Rui

AU - Qi, Jing

AU - Liu, Zhao

AU - Li, Weiwei

AU - An, Jing

AU - Wood, Charles

AU - Wang, Ying

PY - 2017/5/6

Y1 - 2017/5/6

N2 - The conjugation of small ubiquitin-like modifier (SUMO) to the target protein, namely, SUMOylation, is involved in the regulation of many important biological events including host-pathogen interaction. Some viruses have evolved to exploit the host SUMOylation machinery to modify their own protein. Retroviral Gag protein plays critical roles in the viral life cycle. The HIV-1 p6 and the Moloney murine leukemia virus CA have been reported to be conjugated with SUMO. In this study, we report for the first time, to our knowledge, the covalent conjugation of equine infectious anemia virus (EIAV) Gag with SUMO. The C-terminal p9 domain of Gag is a main target for SUMOylation and SUMO is attached to multiple sites of p9, including K30 whose mutation abolished p9 SUMOylation completely. The SUMOylation of p9, but not the p9-K30 mutant, was also detected in equine fibroblastic cells ATCC® CCL-57™. Ubc9 and its C93 residue are indispensable for the SUMOylation of p9. Using confocal microscopy, it is found that EIAV Gag localizes primarily, if not exclusively, in the cytoplasm of the cell and the co-localization of EIAV Gag with Ubc9 was observed. Our findings that EIAV Gag is SUMOylated at p9-K30, together with previous findings on the defects of p9-K30 mutant in viral DNA translocation from cytoplasm to the nucleus, suggests that SUMOylation of Gag may be involved in such functions.

AB - The conjugation of small ubiquitin-like modifier (SUMO) to the target protein, namely, SUMOylation, is involved in the regulation of many important biological events including host-pathogen interaction. Some viruses have evolved to exploit the host SUMOylation machinery to modify their own protein. Retroviral Gag protein plays critical roles in the viral life cycle. The HIV-1 p6 and the Moloney murine leukemia virus CA have been reported to be conjugated with SUMO. In this study, we report for the first time, to our knowledge, the covalent conjugation of equine infectious anemia virus (EIAV) Gag with SUMO. The C-terminal p9 domain of Gag is a main target for SUMOylation and SUMO is attached to multiple sites of p9, including K30 whose mutation abolished p9 SUMOylation completely. The SUMOylation of p9, but not the p9-K30 mutant, was also detected in equine fibroblastic cells ATCC® CCL-57™. Ubc9 and its C93 residue are indispensable for the SUMOylation of p9. Using confocal microscopy, it is found that EIAV Gag localizes primarily, if not exclusively, in the cytoplasm of the cell and the co-localization of EIAV Gag with Ubc9 was observed. Our findings that EIAV Gag is SUMOylated at p9-K30, together with previous findings on the defects of p9-K30 mutant in viral DNA translocation from cytoplasm to the nucleus, suggests that SUMOylation of Gag may be involved in such functions.

KW - EIAV

KW - Gag

KW - K30

KW - SUMO

KW - Ubc9

KW - p9

UR - http://www.scopus.com/inward/record.url?scp=85016051964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016051964&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2017.03.103

DO - 10.1016/j.bbrc.2017.03.103

M3 - Article

C2 - 28342872

AN - SCOPUS:85016051964

VL - 486

SP - 712

EP - 719

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -